Madrigal expands MASH strategy as first Ribo siRNA candidate enters IND preparation
Discover why Ribo and Madrigal’s first nominated siRNA candidate could reshape genetically targeted and combination treatment strategies in MASH.
Pharma & Biotech
Pharma & Biotech
OrsoBio’s TLC-2716 data point to a new oral route in severe metabolic lipid disease
Find out how OrsoBio’s TLC-2716 Phase 2a data could reshape severe hypertriglyceridemia and MASLD drug development.
Pharma & Biotech
insitro’s MASH candidate adds a fibrosis signal, but human proof remains the real test
AI met MASH fibrosis, but mouse data are only the first test. See why insitro’s CTRO-1013 signal matters now.
Pharma & Biotech
Why MetaVia’s higher-dose titration strategy could matter more than the first-patient milestone itself
MetaVia has started higher-dose testing for DA-1726 in obesity. Read what this means for tolerability, competition, and the next clinical milestone.
Pharma & Biotech
Devonian Health Group advances Thykamine with human liver-on-a-chip data targeting fibrosis in MASH
Devonian Health Group reports human liver-on-a-chip data for Thykamine in MASH. See what this means for fibrosis-focused drug development.
Pharma & Biotech
How Madrigal Pharmaceuticals is building a multi-mechanism MASH pipeline with the Phase 2 DGAT-2 inhibitor ervogastat
Find out how Madrigal Pharmaceuticals is building a multi-mechanism MASH pipeline with ervogastat, a Phase 2 oral DGAT-2 inhibitor.